OBJECTIVE	To estimate the costs , benefits and cost effectiveness , from the UK NHS perspective , of fluvastatin ( relative to no HMG-CoA reductase inhibitor [ statin ] ) for the secondary prevention of major adverse cardiac events following a successful first percutaneous coronary intervention ( PCI ) .\